Anti Competitors

Stocks . Taiwan . 
Stock . Anti Microbial Savior BioteQ
6864 Stock   75.00  2.70  3.73%   
Anti Microbial Savior competes with Intech Biopharm, GlycoNex, Sinew Pharma, and Chunghwa Chemical; as well as few others. Analyzing Anti Microbial competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Anti Microbial to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices.

Anti Microbial vs Chunghwa Chemical Correlation

Very good diversification

The correlation between Anti Microbial Savior BioteQ and 1762 is -0.41 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Anti Microbial Savior BioteQ and 1762 in the same portfolio, assuming nothing else is changed.

Moving against Anti Stock

  0.362412 Chunghwa TelecomPairCorr

Anti Microbial Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Anti Microbial and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Anti and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Anti Microbial Savior does not affect the price movement of the other competitor.

High positive correlations

6934
+ 0.96
7729
4168
+ 0.79
6461
6634
+ 0.72
6704
7729
+ 0.57
6892
6934
+ 0.55
6892
4168
+ 0.51
6986
  

High negative correlations

6934
- 0.88
6634
6634
- 0.88
7729
6934
- 0.74
6704
7729
- 0.71
6704
6892
- 0.48
6704
6634
- 0.4
6892

Risk-Adjusted Indicators

There is a big difference between Anti Stock performing well and Anti Microbial Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Anti Microbial's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
6580  1.77 (0.12) 0.00 (0.38) 0.00 
 0.00 
 4.31 
(3.67)
 10.68 
6704  1.10 (0.28) 0.00  1.45  0.00 
 0.00 
 3.23 
(2.78)
 6.10 
6892  1.53  0.07  0.00 (1.31) 1.58 
(2.31)
 7.25 
(2.88)
 12.79 
7729  4.04  1.86  0.69  1.68  1.62 
(5.87)
 16.95 
(5.89)
 24.00 
6461  2.62  0.41  0.11 (0.71) 2.21 
(3.83)
 9.86 
(5.00)
 16.28 
6986  1.51  0.18  0.07  0.62  1.78 
(1.64)
 4.75 
(3.81)
 9.75 
4168  1.81  0.31  0.10 (2.70) 1.92 
(2.22)
 7.23 
(2.70)
 18.02 
6634  1.28 (0.33) 0.00 (3.06) 0.00 
 0.00 
 3.09 
(2.76)
 13.90 
6934  4.73  2.27  0.41 (3.82) 3.04 
(5.54)
 18.06 
(8.04)
 45.51 
1762  0.73  0.01 (0.05) 0.10  0.73 
(1.18)
 1.63 
(1.18)
 9.07 

Anti Microbial Competitive Analysis

The better you understand Anti Microbial competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Anti Microbial's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Anti Microbial's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
6864 6580 6704 6892 7729 6461 6986 4168 6634 6934
 3.73 
 75.00 
Anti
 0.45 
 22.10 
TaiRx
 0.40 
 25.10 
Gwo
 0.18 
 28.40 
Taiwan
 1.13 
 87.30 
Steminent
 2.16 
 21.30 
Intech
 3.39 
 59.80 
HeXun
 0.69 
 28.80 
GlycoNex
 2.76 
 35.25 
Sinew
 3.88 
 148.50 
6934
Market Volatility
(90 Days Market Risk)
Very steady
Not too volatile
Very steady
Very steady
Very steady
Somewhat reliable
Very steady
Very steady
Very steady
Very steady
Market Performance
(90 Days Performance)
Weakest
Weakest
Weakest
Weak
Strong
Fair
Fair
Fair
Weakest
Solid
Odds of Financial Distress
(Probability Of Bankruptcy)
Unknown
Fair
Unknown
Unknown
Unknown
Fair
Unknown
Moderate
High
Unknown
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Fairly Valued
Over Valued
Over Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Sell
Strong Sell
Strong Sell
Buy
Strong Sell
Hold
Hold
Sell
Strong Sell
Current Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
1.31
N/A
Net Asset
N/A
N/A
N/A
N/A
N/A
2.6 B
N/A
1.4 B
N/A
N/A
Profit Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
EBITDA
N/A
N/A
N/A
N/A
N/A
(196.92 M)
N/A
(132.36 M)
(63.06 M)
N/A
Operating Margin
N/A
N/A
N/A
N/A
N/A
-9.09
N/A
-6.59
N/A
N/A
Current Valuation
N/A
N/A
N/A
N/A
N/A
5.09 B
N/A
3.05 B
2.13 B
N/A
Price To Book
N/A
N/A
N/A
N/A
N/A
3.67
N/A
2.37
7.79
N/A
Retained Earnings
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Current Asset
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Five Year Return
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Beta
N/A
N/A
N/A
N/A
N/A
0.59
N/A
1.07
1.63
N/A
Number Of Employees
N/A
8
N/A
N/A
N/A
87
N/A
13
35
N/A
Shares Outstanding
N/A
N/A
N/A
N/A
N/A
116.96 M
N/A
107.1 M
52.29 M
N/A
Cash Flow From Operations
N/A
N/A
N/A
N/A
N/A
(200.61 M)
N/A
(141.08 M)
(59.31 M)
N/A
Annual Yield
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Debt
N/A
N/A
N/A
N/A
N/A
940.77 M
N/A
N/A
2.06 M
N/A
Return On Equity
N/A
N/A
N/A
N/A
N/A
-0.28
N/A
-0.14
-18.48
N/A
Z Score
N/A
N/A
N/A
N/A
N/A
1.8
N/A
N/A
N/A
N/A
Return On Asset
N/A
N/A
N/A
N/A
N/A
-0.0739
N/A
-0.0844
-5.47
N/A
Book Value Per Share
N/A
N/A
N/A
N/A
N/A
9.61
N/A
14.6
8.33
N/A
Current Liabilities
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Asset
N/A
N/A
N/A
N/A
N/A
2.6 B
N/A
1.4 B
N/A
N/A
Debt To Equity
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.005
N/A
Target Price
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Last Dividend Paid
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Shares Owned By Institutions
N/A
N/A
N/A
N/A
N/A
6.26
N/A
0.1
N/A
N/A
Market Capitalization
N/A
1.28 B
N/A
N/A
N/A
3.71 B
N/A
3.43 B
3.39 B
N/A
Price To Earning
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Price To Sales
N/A
N/A
N/A
N/A
N/A
128.48
N/A
111.08
616.01
N/A
Net Income
N/A
N/A
N/A
N/A
N/A
(301.76 M)
N/A
(172.49 M)
(81.08 M)
N/A
Earnings Per Share
N/A
N/A
N/A
N/A
N/A
-2.87
N/A
-1.66
-1.65
N/A
Shares Owned By Insiders
N/A
N/A
N/A
N/A
N/A
47.02
N/A
21.44
N/A
N/A
Revenue
N/A
N/A
N/A
N/A
N/A
38.9 M
N/A
5.47 M
5.51 M
N/A
Working Capital
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash And Equivalents
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
1.31 B
N/A
Cash Per Share
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
24.84
N/A
Gross Profit
N/A
N/A
N/A
N/A
N/A
(119.37 M)
N/A
3.46 M
324 K
N/A
Day Typical Price
73.93
21.9
24.92
28.32
87.3
21.43
59.93
28.83
35.47
151.5
Accumulation Distribution
0.0479
0.0271
0.0219
0.0158
0.0686
0.0631
0.0328
0.0307
0.0399
0.0935
Market Facilitation Index
3.6
0.6
0.55
0.45
6.2
1.4
2.0
0.9
1.45
15.0
Daily Balance Of Power
0.75
0.1667
0.1818
(0.11)
(0.16)
0.3214
(1.05)
(0.22)
(0.69)
(0.40)
Period Momentum Indicator
2.7
0.1
0.1
(0.05)
(1.00)
0.45
(2.10)
(0.20)
(1.00)
(6.00)
Rate Of Daily Change
1.04
1.0
1.0
1.0
0.99
1.02
0.97
0.99
0.97
0.96
Day Median Price
73.4
21.8
24.83
28.28
87.3
21.5
60.0
28.85
35.58
153.0
Price Action Indicator
2.95
0.35
0.33
0.1
(0.50)
0.025
(1.25)
(0.15)
(0.82)
(7.50)
Relative Strength Index
N/A
47.02
N/A
N/A
N/A
59.78
N/A
64.23
N/A
N/A
Coefficient Of Variation
(1,299)
(2,440)
(544.78)
3031.25
279.17
992.49
966.46
940.27
(678.88)
339.28
Mean Deviation
1.22
1.77
1.1
1.53
4.04
2.62
1.51
1.81
1.28
4.73
Jensen Alpha
(0.12)
(0.12)
(0.28)
0.072
1.86
0.4116
0.1849
0.305
(0.33)
2.27
Total Risk Alpha
(0.31)
(0.32)
(0.44)
(0.15)
1.43
0.0183
0.0113
0.0276
(0.53)
1.52
Sortino Ratio
N/A
N/A
N/A
1.0E-4
0.6944
0.1122
0.065
0.101
N/A
0.4129
Downside Variance
N/A
N/A
N/A
2.68
7.28
7.49
4.62
5.14
N/A
27.47
Standard Deviation
1.75
2.32
1.55
2.38
5.45
3.82
2.11
2.89
2.14
7.61
Kurtosis
1.31
(0.03)
0.8365
3.88
2.09
1.6
0.9501
3.73
12.41
9.08
Potential Upside
3.75
4.31
3.23
7.25
16.95
9.86
4.75
7.23
3.09
18.06
Treynor Ratio
0.4763
(0.38)
1.45
(1.31)
1.68
(0.71)
0.6154
(2.70)
(3.06)
(3.82)
Maximum Drawdown
8.5
10.68
6.1
12.79
24.0
16.28
9.75
18.02
13.9
45.51
Variance
3.08
5.39
2.41
5.66
29.69
14.62
4.44
8.36
4.59
57.88
Market Risk Adjusted Performance
0.4863
(0.37)
1.46
(1.30)
1.69
(0.70)
0.6254
(2.69)
(3.05)
(3.81)
Risk Adjusted Performance
(0.05)
(0.02)
(0.13)
0.0311
0.2709
0.0819
0.0823
0.0853
(0.10)
0.2248
Skewness
0.8526
0.2118
0.0198
1.39
1.45
1.29
0.3487
1.06
(2.52)
2.37
Semi Deviation
N/A
N/A
N/A
1.58
1.62
2.21
1.78
1.92
N/A
3.04
Information Ratio
(0.12)
(0.07)
(0.23)
0.0
0.3438
0.0803
0.0663
0.0793
(0.18)
0.2844
Value At Risk
(2.49)
(3.67)
(2.78)
(2.88)
(5.89)
(5.00)
(3.81)
(2.70)
(2.76)
(8.04)
Expected Short fall
N/A
N/A
N/A
(2.31)
(5.87)
(3.83)
(1.64)
(2.22)
N/A
(5.54)
Downside Deviation
N/A
N/A
N/A
1.64
2.7
2.74
2.15
2.27
N/A
5.24
Semi Variance
N/A
N/A
N/A
2.49
2.63
4.89
3.17
3.68
N/A
9.24

Anti Microbial Competition Performance Charts

Five steps to successful analysis of Anti Microbial Competition

Anti Microbial's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Anti Microbial Savior in relation to its competition. Anti Microbial's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Anti Microbial in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Anti Microbial's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Anti Microbial Savior, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Anti Microbial position

In addition to having Anti Microbial in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Entertainment Thematic Idea Now

Entertainment
Entertainment Theme
Companies from entertainment industry including show business, news and media. The Entertainment theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Entertainment Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Anti Stock Analysis

When running Anti Microbial's price analysis, check to measure Anti Microbial's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anti Microbial is operating at the current time. Most of Anti Microbial's value examination focuses on studying past and present price action to predict the probability of Anti Microbial's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anti Microbial's price. Additionally, you may evaluate how the addition of Anti Microbial to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY